Stockscreener 앱 받기
4.37
4.79%
-0.22
시간 외 거래:
4.47
0.10
+2.29%
Vanda Pharmaceuticals Inc 주식(VNDA)의 최신 뉴스
A Glimpse of Vanda Pharma's Earnings Potential - Nasdaq
3 Penny Stocks Under $300M Market Cap To Consider - simplywall.st
Allergic Conjunctivitis Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, and Latest Developments Unveiled by DelveInsight | Bausch & Lomb Inc, Aldeyra Therapeutics, Vanda Pharma, OKYO Pharma - Barchart.com
Drugmaker Vanda Announces Bysanti NDA Filing - marketscreener.com
FDA accepts Vanda’s new antipsychotic drug for review - Investing.com
Vanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026 | VNDA Stock News - GuruFocus
FDA Begins Review Process on Vanda Pharmaceuticals' (VNDA) Drug Application | VNDA Stock News - GuruFocus
FDA Sets 2026 Decision Date for Vanda's New Mental Health Drug with 20+ Year Patent Life - Stock Titan
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - BioSpace
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial R - GuruFocus
Press Release Distribution & PR Platform - ACCESS Newswire
Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 | VNDA Stock News - GuruFocus
Vanda Pharmaceuticals Earnings Alert: Key Q1 2025 Financial Results Drop May 7 After Market Close - Stock Titan
FDA delays Vanda Pharmaceuticals drug hearing By Investing.com - Investing.com India
FDA delays Vanda Pharmaceuticals drug hearing - Investing.com Australia
Vanda claims FDA 'unlawfully' delays hearing request on tradipitant decision - MSN
Vanda Pharmaceuticals (VNDA) Criticizes FDA Over Tradipitant Hea - GuruFocus
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and False - GuruFocus
FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA – Company AnnouncementFT.com - Financial Times
Recent FDA staff cuts to delay drug hearing decision by months, agency tells Vanda - Endpoints News
Capitals Announce ALL CAPS 2025 Playoffs Initiatives Presented by Vanda Pharmaceuticals Inc. - NHL.com
FDA Drug Rules Under Fire in Pharma Free Speech Fight - Law360
Vanda Sues FDA To Block Off-Label Use Drug Promo Regs - Law360
Vanda Pharmaceuticals: Financials Are Great, But Market Reaction Is Confusing (VNDA) - Seeking Alpha
Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting - Nasdaq
FDA-Designated Precision Medicine Breakthrough: New Hope for Rare Genetic Disease Patients - Stock Titan
Class Action Update Vanda Pharmaceuticals Inc. (VNDA) & Stamps.com Inc. (STMP)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Class Action Update Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
Class Action Notice Vanda Pharmaceuticals Inc. (VNDA), Stamps.com Inc. (STMP) & Syneos Health, Inc. (SYNH)Bronstein, Gewirtz & Grossman, LLC - ACCESS Newswire
High Growth Tech Stocks In US With Promising Potential - simplywall.st
Forecasting The Future: 5 Analyst Projections For Vanda Pharmaceuticals - Benzinga
Vanda Pharmaceuticals Seeks US FDA Approval for Bysanti to Treat Schizophrenia, Acute Bipolar I Disorder - MarketScreener
Vanda Pharmaceuticals submits NDA to FDA for Bysanti - TipRanks
Vanda seeks FDA nod for new bipolar, schizophrenia drug - Investing.com
Vanda seeks FDA nod for new bipolar, schizophrenia drug By Investing.com - Investing.com UK
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - PR Newswire
HC Wainwright maintains $20 target on Vanda Pharmaceuticals stock By Investing.com - Investing.com UK
Vanda Raises Concerns Over FDA Review Timeline for Motion Sickness Therapy Candidate - MarketScreener
Vanda Pharmaceuticals announces FDA review date for new drug By Investing.com - Investing.com South Africa
Vanda Pharmaceuticals announces FDA review date for new drug - Investing.com
Vanda Pharmaceuticals’ New Drug Application Accepted by FDA - TipRanks
5.24%
자본화:
|
볼륨(24시간):